Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) Net Margin (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Net Margin for 7 consecutive years, with 201.92% as the latest value for Q1 2025.

  • Quarterly Net Margin rose 13972.0% to 201.92% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 26.68% through Dec 2025, up 27179.0% year-over-year, with the annual reading at 288.26% for FY2025, 4313.0% down from the prior year.
  • Net Margin for Q1 2025 was 201.92% at Whitehawk Therapeutics, up from 252.42% in the prior quarter.
  • The five-year high for Net Margin was 114.23% in Q4 2021, with the low at 3701.45% in Q1 2021.
  • Average Net Margin over 5 years is 522.73%, with a median of 266.18% recorded in 2022.
  • Peak annual rise in Net Margin hit 310080bps in 2022, while the deepest fall reached -15195bps in 2022.
  • Over 5 years, Net Margin stood at 114.23% in 2021, then crashed by -133bps to 266.18% in 2022, then grew by 3bps to 257.18% in 2023, then grew by 2bps to 252.42% in 2024, then increased by 20bps to 201.92% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 201.92%, 252.42%, and 173.95% for Q1 2025, Q4 2024, and Q3 2024 respectively.